MannKind Corp. (NASDAQ:MNKD) COO Hakan Edstrom bought 1,589 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was purchased at an average cost of $4.53 per share, with a total value of $7,198.17. Following the acquisition, the chief operating officer now directly owns 729,685 shares of the company’s stock, valued at approximately $3,305,473. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of MannKind Corp. in a research note to investors on Monday, December 30th. They now have a $5.50 price target on the stock. Separately, analysts at Piper Jaffray initiated coverage on shares of MannKind Corp. in a research note to investors on Tuesday, November 26th. They set a “neutral” rating and a $5.00 price target on the stock. Finally, analysts at MLV Capital cut their price target on shares of MannKind Corp. from $11.00 to $10.00 in a research note to investors on Wednesday, November 6th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. MannKind Corp. currently has a consensus rating of “Hold” and an average target price of $6.38.
Shares of MannKind Corp. (NASDAQ:MNKD) traded up 4.26% on Monday, hitting $5.63. 4,689,635 shares of the company’s stock traded hands. MannKind Corp. has a 1-year low of $2.34 and a 1-year high of $8.70. The stock has a 50-day moving average of $5.05 and a 200-day moving average of $5.89. The company’s market cap is $1.695 billion.
MannKind Corp. (NASDAQ:MNKD) last posted its quarterly earnings results on Monday, November 4th. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.14) by $0.03. During the same quarter in the prior year, the company posted ($0.22) earnings per share. The company’s quarterly revenue was down 100.0% on a year-over-year basis. Analysts expect that MannKind Corp. will post $-0.62 EPS for the current fiscal year.
MannKind Corporation (NASDAQ:MNKD) is a development-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.